Forxiga Signed Off for Treatment of HF and HFrEF

In Europe alone, approximately 15 million individuals experience some level of heart failure (HF). This is a long-lasting, degenerative illness that worsens over time.

Nearly 50% of patients with this condition pass away less than five years post diagnosis, and individuals with Heart failure with midrange ejection fraction (HFmrEF) and Heart failure with preserved ejection fraction (HFpEF) have a higher chance of requiring hospitalisation or dying. This is because their symptoms are frequently covered up by other medical problems, with HFmrEF and HFpEF remaining significantly underdiagnosed.

However, there is good news as the EU has signed off AstraZeneca’s Forxiga therapy to also include HF with a reduced ejection fraction (HFrEF).

This means the treatment will now cover individuals who have any amount of left ventricular ejection fraction (LVEF).

This follows the Committee for Medicinal Products for Human Use’s initial endorsement of the drug a couple of months ago due to encouraging findings from the DELIVER stage 3 clinical study.

AstraZeneca’s Forxiga is currently the only treatment of this kind on the market to demonstrate increased mortality throughout all levels of ejection fractions.

Astrazeneca’s BioPharmaceuticals R&D Executive VP, Mene Pangalos, said that they “are redefining treatment of cardiorenal diseases with Forxiga’s demonstration of life-saving benefits, underscoring AstraZeneca’s commitment to address the complexities of heart failure across the spectrum of the disease.”

So far Forxiga has been signed off for patients with type 2 HFrEF, diabetes and CKD in over 100 countries globally.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.